HK1220385A1 - 用於增加瘦素生成的比马前列素 - Google Patents

用於增加瘦素生成的比马前列素 Download PDF

Info

Publication number
HK1220385A1
HK1220385A1 HK16108521.3A HK16108521A HK1220385A1 HK 1220385 A1 HK1220385 A1 HK 1220385A1 HK 16108521 A HK16108521 A HK 16108521A HK 1220385 A1 HK1220385 A1 HK 1220385A1
Authority
HK
Hong Kong
Prior art keywords
bimatoprost
enhancement
leptin production
leptin
production
Prior art date
Application number
HK16108521.3A
Other languages
English (en)
Chinese (zh)
Inventor
Neil J. POLOSO
Robert M. Burk
Michael E. Garst
David F. Woodward
Timothy J. Maziasz
Suzanne Kanaly
Grantley CHARLES
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of HK1220385A1 publication Critical patent/HK1220385A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16108521.3A 2013-03-15 2014-03-13 用於增加瘦素生成的比马前列素 HK1220385A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
US201361793132P 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (1)

Publication Number Publication Date
HK1220385A1 true HK1220385A1 (zh) 2017-05-05

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108521.3A HK1220385A1 (zh) 2013-03-15 2014-03-13 用於增加瘦素生成的比马前列素

Country Status (11)

Country Link
US (2) US20140275272A1 (https=)
EP (1) EP2968361A1 (https=)
JP (1) JP2016513647A (https=)
KR (1) KR20150129735A (https=)
CN (1) CN105338985A (https=)
AU (1) AU2014228307A1 (https=)
BR (1) BR112015021859A2 (https=)
CA (1) CA2901529A1 (https=)
HK (1) HK1220385A1 (https=)
RU (1) RU2015134772A (https=)
WO (1) WO2014143629A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
ES2687494T3 (es) * 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal

Also Published As

Publication number Publication date
JP2016513647A (ja) 2016-05-16
BR112015021859A2 (pt) 2017-07-18
WO2014143629A1 (en) 2014-09-18
RU2015134772A3 (https=) 2018-03-21
US20160310505A1 (en) 2016-10-27
CN105338985A (zh) 2016-02-17
CA2901529A1 (en) 2014-09-18
US20140275272A1 (en) 2014-09-18
RU2015134772A (ru) 2017-04-21
AU2014228307A1 (en) 2015-09-10
KR20150129735A (ko) 2015-11-20
EP2968361A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP3031141B8 (en) Cancellation of non-linear digital self-interferences
EP3229997A4 (en) Additive manufacturing of metallic structures
HK1245719A1 (en) Additive manufacturing of metallic structures
EP3224708A4 (en) Competing devices responding to voice triggers
EP3033425A4 (en) Compositions and methods for modulating expression of frataxin
EP2938812A4 (en) Method of assembly for sand screen
PT3105757T (pt) Extensão da largura de banda harmónica de sinais de áudio
EP3315535A4 (en) PROCESS FOR PRODUCING CONJUGATED DIENE RUBBER
EP3033347A4 (en) Compositions and methods for making noscapine and synthesis intermediates thereof
WO2014147640A3 (en) Process for the preparation of anagliptin
EP3049079A4 (en) Solid forms of ceftolozane
EP3235501A4 (en) Application of derivative of clostridium ghonii
EP3021840A4 (en) Methods and compositions for prevention of allergic reaction
EP3371141A4 (en) Production of cyclic c5 compounds
EP3468578A4 (en) USES OF IL-41
EP3100230A4 (en) Segments of contacts
EP3303364A4 (en) Production of sterols
EP3263909A4 (en) Method of manufacturing turbocharger
EP3320901A4 (en) Application of dimethylamino micheliolide
EP3706740A4 (en) METHOD FOR MANUFACTURING ACALABRUTINIB
EP3356493B8 (en) Redispersion of schizophyllan
HK1220385A1 (zh) 用於增加瘦素生成的比马前列素
EP3253770A4 (en) Method of producing organohalosilanes
HK1219650A1 (zh) 对映黄体酮及其中间产物的合成
EP2786402B8 (en) Method of mechanosynthetic manufacture